How animal health closed a 30-year innovation gap—and why the payback window is now shorter
Animal health spent most of its modern history as the beneficiary of somebody else’s research. That arrangement ended over the course of roughly a decade, and how the industry responded is the story its numbers now tell. Three things follow from it. The industry built an innovation ecosystem it owns. It closed a technology gap with human health that once ran to 30 years. And it now has materially less time to earn back the cost of each launch.
An industry that lost its R&D parent
Between 2010 and 2018, five transactions separated animal health from the human pharmaceutical companies that had been supplying it: Elanco bought Janssen’s animal health business, Zoetis spun off from Pfizer, Elanco acquired Novartis’ animal health business, Boehringer Ingelheim bought Merial from Sanofi, and Elanco itself was spun off from Eli Lilly. Measured against the 2017 R&D budgets of those five parent companies, the sector’s cumulative loss of access to external discovery spending came to $37.3 billion.
The dependency being severed was real. Historically, more than half of animal health products were derived from compounds that originated in in-house human pharma R&D. The pipeline was inherited rather than built.
A self-funded ecosystem grew in its place
Roughly 578 animal health startups are active globally in 2026. Some 251 of them—43%—work in therapeutics, and the concentration within that group maps closely onto where companion animal medicine is short of options: 66 startups in pain, 61 in oncology, 38 in mobility and 29 in dermatology.
Capital followed. Seventeen of the 20 largest private equity funds hold an animal or pet asset today, against five at the end of 2015, with the roster running from KKR and EQT through Blackstone, TPG, Bain Capital, General Atlantic and Advent International. Exit options for a startup have widened accordingly.
The development economics explain the interest. Compared with human health, an animal health program carries a higher probability of success at every stage of development, runs on timelines roughly 50% shorter, and faces expected development costs up to 70 times lower. For an investor weighing a portfolio of shots on goal, that combination is difficult to ignore.
From a 30-year lag to none
The clearest evidence that the replacement ecosystem works is the speed at which proven platform technologies now cross over from human medicine. Monoclonal antibodies took 30 years: J&J launched Orthoclone OKT3 in 1986; Zoetis launched Cytopoint in 2016. mTOR inhibitors took 26 years, from Wyeth’s Rapamune in 1999 to TriviumVet’s Felycin-CA1 in 2025. LFA-1 inhibitors took 15: Genentech’s Raptiva in 2003, ISK’s Brenda in 2018. SGLT2 inhibitors took 11: J&J’s Invokana in 2013, Elanco’s Bexacat in 2024. PD-1 checkpoint inhibitors took nine, from MSD’s Keytruda in 2014 to MSD Animal Health’s Gilvetmab in 2023. Regenerative cell therapy took one: Takeda’s Alofisel in 2018 followed by Boehringer’s Arti-Cell Forte in 2019. And with CRISPR gene editing the lag disappeared entirely: Vertex’s Casgevy and Genus’s PRRS-resistant pig both arrived in 2023.
Thirty years, 26, 15, 11, nine, one, none. A sector that once waited a generation for a validated modality now adopts it in the same cycle as human medicine.
What that innovation has delivered
With that innovation has come growth, mostly through new products. The global companion animal market grew from $10.8 billion in 2015 to $22.7 billion in 2025, a 7.7% compound annual rate. Of the $11.9 billion added, $8.0 billion (67%) came from brands launched after the start of 2014. Those launches contributed 3.1 percentage points of CAGR on their own. The rest of the portfolio accounted for the remaining $3.9 billion.
Atopic dermatitis shows what a single well-chosen therapeutic area can do. Global sales in Zoetis’s dermatology franchise, built on Apoquel and then Cytopoint, ran below $1 million in 2013, reached $34 million in 2014 and $248 million in 2016, and stood at $1.74 billion in 2025. Treatment options for canine atopic dermatitis existed before it. What a targeted therapy did was expand the treated population by an order of magnitude. Innovation matters more from here rather than less, because the base is slowing. On Stonehaven Cozmix Group’s Market Model, companion animal grows from $22.7 billion in 2025 to $31.9 billion in 2031, a 5.8% rate—190 basis points below the previous decade. New launches account for $5.8 billion of the $9.2 billion increase, or 63%, but they contribute 2.3 points of CAGR against 3.1 points previously, 80 basis points less. Existing products supply the other $3.4 billion. Growth is becoming more dependent on products that have not launched yet, at the same time as the overall rate moderates.
Why the payback window is shorter
The offsetting pressure is generic entry, and it has accelerated sharply. US FDA ANADA approvals ran eight, nine, 10, 31 and 19 across 2016 to 2020—77 in total. Across 2021 to 2025 the same series reads 36, 18, 33, 27 and 31, or 145. A 1.9x increase in five years.
More consequential than the volume is the timing. The long tail after patent expiration has gone. Rimadyl (carprofen) lost exclusivity in 2002 and drew a single generic entrant within five years, with the field filling out only across the following two decades. Draxxin (tulathromycin) lost exclusivity in 2020 and drew 14 within five years. An originator that once faced a decade of gentle erosion now faces a cliff.
Thirteen active ingredients lose US exclusivity between 2026 and 2031. The largest are oclacitinib at $420 million of 2026 US sales, fluralaner at $410 million and afoxolaner at $410 million, followed by pimobendan at $130 million, grapiprant at $80 million and trilostane at $60 million, with pergolide, tildipirosin, gamithromycin, methimazole, telmisartan, tilmicosin and furosemide behind them. Around $1.6 billion of current US sales moves into open competition inside five years.
The strategic consequence is arithmetic. With fewer protected years to recover development cost, either the product must be differentiated enough to hold price through the transition, or the cost of creating it must be lower. Both routes are live, and the second is underrated.
The unglamorous fix often beats the breakthrough
A significant share of value creation in animal health comes from changing how a molecule is presented rather than from finding a new one.
- Reformulation: Apoquel moved from a tablet to a chewable.
- Combination: Draxxin became Draxxin KP with the addition of ketoprofen, and NexGard chew became NexGard Spectra with heartworm and intestinal worm coverage added.
- Route of delivery: Mirtazapine, an appetite stimulant that is difficult to administer orally to a cat, became the transdermal Mirataz.
- Application design: A pistol-grip drench gun that causes wrist strain became the Simcro Optiline, whose inline nozzle removes the wrist rotation altogether.
- Duration: Merck Animal Health’s Bravecto Quantum, a single injection covering a full year, drew 47% of its starting dogs from owners who had not previously been buying flea and tick control from their veterinarian, making it one of the few parasiticides in decades shown to grow the veterinary market rather than shift share from one vet brand to another.1
None of these required a new platform. All of them changed whether the product gets used correctly, which is what determines whether it earns revenue. The same logic extends beyond the product itself: Vetcove innovated how veterinarians buy rather than what they buy, moving from 4% of US clinics in 2016 to around 61% in 2026, compound growth of 32% a year.
Where the next decade is won
In companion animals, six unmet needs define the next era: oncology, nephrology, endocrinology including metabolic syndrome and obesity, cardiology, longevity and specialized diagnostics. Each is estimated at $1 billion or more globally, with nephrology and specialized diagnostics the largest at up to $3 billion, set against established areas of $10 billion for parasiticides, $3 billion for dermatology and $2 billion for pain management. Oncology may be at an inflection point: 61 of the sector’s 578 startups already work there, and the US companion animal oncology market is on a rising trajectory through 2031 from a small base.
Longer lifespans are helping make those categories inevitable. Life expectancy at birth for US dogs rose from an estimated 9.1 years in 1981 to a measured 12.69 years across 2013-19, an increase of 39%. For US cats the same comparison runs from 5.4 to 11.18 years: 106%, more than doubling. Japanese industry estimates put dogs half again as long-lived as they were in 1980. Pets living close to twice as long present chronic disease, and chronic disease is a different commercial proposition from an acute course of treatment.
In production animals the gaps sit in monitoring, diagnostics and treatment cycles rather than in the established categories of vaccines ($10 billion), anti-infectives ($5 billion), parasiticides ($3 billion) and reproduction and fertility management ($1 billion). Six areas stand out: alternatives to antibiotics, as precision medicine replaces routine use; next-generation vaccine platforms moving toward universal coverage as care shifts to prevention; on-farm diagnostics fast enough to inform a decision at the animal; genetics and disease resistance, where the first FDA-approved gene-edited pigs for PRRS resistance have opened the field; monitoring and wearables, where collars allow continuous observation of individual animals and earlier diagnosis; and production and sustainability, which is becoming a commercial category rather than a compliance cost.
The structural backdrop reinforces all six. Farms continue to grow larger, particularly in the US. Skilled labor is becoming scarcer. Data is arriving in real time, farm automation continues to rise, and centralized data storage is emerging as the precondition for extracting value from any of it.
From products to solutions
Those two lists point the same direction. The gaps are not in any single product; they sit in the sequence around it: monitoring the animal, diagnosing earlier, treating precisely, and managing the condition over time. The unit of competition is moving from the product to that cycle. The implication for manufacturers is that a position across several of its steps may prove more durable than ownership of the best individual molecule.
AI is already operating inside that shift, past the pilot stage. At the pet owner-veterinarian interface, Sylvester AI uses computer vision and feline pain science to assess a cat’s condition from images or video; the technology was developed on real-world cat images and validated by veterinarians against an established feline pain assessment framework. In the interpretation of large datasets, IDEXX’s DecisionIQ, integrated into VetConnect PLUS, reads patterns across laboratory results, clinical histories and longitudinal patient data alongside clinician input, flagging abnormalities to support earlier diagnosis.
The conclusion the data supports
The Animal Health Industry lost access to $37.3 billion of adjacent R&D capacity and replaced it with 578 startups and a private equity market 17 funds deep. It closed a 30-year technology lag to zero. It is generating two-thirds of its growth from products launched within the last decade. And it now faces generic entry roughly twice as fast as five years ago, with $1.6 billion of US sales losing exclusivity by 2031.
That is not the profile of a slowing industry. It is the profile of an industry working against a shorter clock, in which returns concentrate among those who pick the unmet need correctly, execute the unglamorous improvements that determine whether a product is actually used, and connect what they sell into the solution their customer is already trying to assemble.
1. Kynetec Adhoc Analysis Adult New Bravecto Quantum Dog Patients and Source of Volume August 2025–June 2026.
Chad’s email: chad.terrell@sc.group
Juerg’s email : JB@sc.group